Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
Johnson and Johnson
UBS
Colorcon
Cerilliant
Covington
Farmers Insurance
Julphar

Generated: September 24, 2018

DrugPatentWatch Database Preview

TRILEPTAL Drug Profile

« Back to Dashboard

When do Trileptal patents expire, and what generic alternatives are available?

Trileptal is a drug marketed by Novartis and is included in two NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in TRILEPTAL is oxcarbazepine. There are nineteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.

Drug patent expirations by year for TRILEPTAL
Pharmacology for TRILEPTAL
Synonyms for TRILEPTAL
10-oxo-10,11-dihydro-5H-dibenz(b,f)azepin-5-carboxamide
10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide
10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide #
10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide
10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide
10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carbonsaeureamid
10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide
10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; Oxacarbazepine
10,11-Dihydro-10-oxo-5H-dibenzo(Z)[b,f]azepine-5-carboxamide
10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide
28721-07-5
5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine
5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
5H-Dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-oxo-
5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo-
721O075
9-oxo-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide
9-oxo-2-azatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide
9-OXO-2-AZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(15),3,5,7,11,13-HEXAENE-2-CARBOXAMIDE
AB0012847
AB00393017_15
AB00393017_16
AB00393017-12
AB00393017-14
AB1004555
AC-3483
AC1L1RCU
AC1Q6NA8
AKOS005516529
AM20040094
AN-6739
API0003702
BB_SC-01874
BBL010789
BC204104
BDBM34179
BG0593
BIDD:GT0078
Bio-0527
BSPBio_003457
C-15585
C07492
CAS-28721-07-5
CC-33410
CCG-39509
CHEBI:7824
CHEMBL1068
cid_34312
CPD000048684
CS-1869
CTRLABGOLIVAIY-UHFFFAOYSA-N
D00533
D0QL3P
DB00776
Desitin brand of oxcarbazepine
DR000685
DSSTox_CID_25703
DSSTox_GSID_45703
DSSTox_RID_81075
DTXSID0045703
EINECS 249-188-8
EN300-123538
Epilexter
Epliga
FT-0630543
GP 47680
GP-47680
GTPL7254
HMS1922H17
HMS2051O04
HMS2090F13
HMS2093E10
HMS2231B12
HMS3369J22
HMS3393O04
HMS3657O11
HSDB 7524
HY-B0114
I06-0072
J10384
KBio2_002155
KBio2_004723
KBio2_007291
KBio3_002677
KBioGR_001248
KBioSS_002155
KIN-493
KS-5197
LS-60365
MCULE-9100100302
MFCD00865307
MLS000084586
MLS000759520
MLS001201742
MLS001424025
MLS006011855
MolPort-001-685-316
NC00088
NCGC00065934-02
NCGC00065934-03
NCGC00065934-04
NCGC00065934-05
NCGC00065934-06
Novartis brand of oxcarbazepine
NSC-758693
NSC758693
O0363
OCBZ
Opera_ID_818
Oxacarbazepine
Oxaleptal (TN)
Oxcarbamazepine
Oxcarbazepime
Oxcarbazepin
Oxcarbazepina
Oxcarbazepina [INN-Spanish]
OXCARBAZEPINE
Oxcarbazepine (JAN/USAN/INN)
Oxcarbazepine (USAN/INN)
Oxcarbazepine [INN]
Oxcarbazepine [USAN:USP:INN:BAN]
Oxcarbazepine-13C6 solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material
Oxcarbazepine-d4
Oxcarbazepine, >=98% (HPLC), solid
Oxcarbazepine, analytical standard
Oxcarbazepine, European Pharmacopoeia (EP) Reference Standard
Oxcarbazepine, United States Pharmacopeia (USP) Reference Standard
Oxcarbazepinum
Oxcarbazepinum [INN-Latin]
oxecarb
Oxtellar (TN)
Pharmakon1600-01504243
PL039783
regid866068
s1391
SAM001246754
SBI-0206772.P001
SC-16252
SCHEMBL35129
SMR000048684
SPBio_000345
Spectrum_001675
SPECTRUM1504243
Spectrum2_000483
Spectrum3_001669
Spectrum4_000634
Spectrum5_001869
SPN-804
STK594696
Timox
Tox21_110983
Tox21_110983_1
Trileptal (TN)
UNII-VZI5B1W380
VZI5B1W380
W-107033
W-2542
ZB000586
ZINC4724

US Patents and Regulatory Information for TRILEPTAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis TRILEPTAL oxcarbazepine SUSPENSION;ORAL 021285-001 May 25, 2001 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-002 Jan 14, 2000 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis TRILEPTAL oxcarbazepine SUSPENSION;ORAL 021285-001 May 25, 2001 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-001 Jan 14, 2000 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-003 Jan 14, 2000 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for TRILEPTAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis TRILEPTAL oxcarbazepine SUSPENSION;ORAL 021285-001 May 25, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-002 Jan 14, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-001 Jan 14, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-003 Jan 14, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TRILEPTAL
Drugname Dosage Strength RLD Date
➤ Subscribe Oral Suspension 300 mg/5 mL ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Tablets 150 mg, 300 mg and 600 mg ➤ Subscribe ➤ Try a Free Trial

International Patents for TRILEPTAL

Country Document Number Estimated Expiration
Spain 2223641 ➤ Try a Free Trial
Poland 201331 ➤ Try a Free Trial
China 1626093 ➤ Try a Free Trial
Slovakia 287553 ➤ Try a Free Trial
Australia 2511801 ➤ Try a Free Trial
Russian Federation 2002119210 ➤ Try a Free Trial
South Korea 20090037873 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
Johnson and Johnson
UBS
Colorcon
Cerilliant
Covington
Farmers Insurance
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.